Synapse - Howard Scher

Results (1133)

Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)

Meeting Abstract

Montgomery, R. B.; San Kheoh, T.; Molina, A.; Li, J.; Bellmunt, J.; Ryan, C. J.; Tran, N.; Loriot, Y.; Efstathiou, E.; Scher, H. I.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

Meeting Abstract

Loriot, Y.; Fizazi, K.; De Bono, J. S.; Forer, D.; Hirmand, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Feasibility of long-term patient reporting of toxicities from home via the internet during routine chemotherapy

Meeting Abstract

Judson, T. J.; Bennett, A. V.; Rogak, L. J.; Sit, L.; Barz, A.; Kris, M. G.; Hudis, C.; Scher, H. I.; Sabbatini, P.; Schrag, D.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib

Meeting Abstract

Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer

Meeting Abstract

Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel

Meeting Abstract

Chi, K. N.; San Kheoh, T.; Ryan, C. J.; Molina, A.; Bellmunt, J.; Vogelzang, N. J.; Rathkopf, D. E.; Fizazi, K.; Kantoff, P. W.; Li, J.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Computer-aided bone scan lesion area quantitation: Inter-reader measurement variability

Meeting Abstract

Chu, G. H.; Brown, M. S.; Kim, H. J.; Kaplan, A.; Yang, K.; Allen-Auerbach, M.; Poon, C.; Levine, B.; Schiepers, C.; Verma, R.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Bianchini, D.; Omlin, A. G.; Pezaro, C. J.; Mukherji, D.; Estelles, D. L.; Zivi, A.; Ferraldeschi, R.; Crespo, M.; Buchbinder, A.; Attard, G.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Attard, G.; De Bono, J. S.; Li, W.; Molina, A.; Griffin, T. W.; Kheoh, T. S.; Ricci, D. S.; Zelinsky, K.; Rathkopf, D. E.; Scher, H. I.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save